213 related articles for article (PubMed ID: 23342885)
1. [Uterine carcinosarcoma].
Serkies K; Jassem J
Ginekol Pol; 2012 Aug; 83(8):609-12. PubMed ID: 23342885
[TBL] [Abstract][Full Text] [Related]
2. Eleven years: the long and winding road.
Ramondetta LM; Jhingran A
Gynecol Oncol; 2007 Nov; 107(2):166-8. PubMed ID: 17950382
[No Abstract] [Full Text] [Related]
3. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
Wolfson AH; Brady MF; Rocereto T; Mannel RS; Lee YC; Futoran RJ; Cohn DE; Ioffe OB
Gynecol Oncol; 2007 Nov; 107(2):177-85. PubMed ID: 17822748
[TBL] [Abstract][Full Text] [Related]
4. Review of Recommended Treatment of Uterine Carcinosarcoma.
Menczer J
Curr Treat Options Oncol; 2015 Nov; 16(11):53. PubMed ID: 26374341
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study.
Guttmann DM; Li H; Sevak P; Grover S; Jacobson G; Feldman A; Rubin S; Chu C; Bhatia S; Elshaikh MA; Lin LL
Int J Gynecol Cancer; 2016 Jan; 26(1):141-8. PubMed ID: 26509850
[TBL] [Abstract][Full Text] [Related]
6. Early-stage carcinosarcoma of the uterus: the significance of lymph node count.
Temkin SM; Hellmann M; Lee YC; Abulafia O
Int J Gynecol Cancer; 2007; 17(1):215-9. PubMed ID: 17291256
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of adjuvant pelvic radiation "sandwiched" between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma.
Einstein MH; Klobocista M; Hou JY; Lee S; Mutyala S; Mehta K; Reimers LL; Kuo DY; Huang GS; Goldberg GL
Gynecol Oncol; 2012 Jan; 124(1):26-30. PubMed ID: 22055846
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel and carboplatin in patients with completely or optimally resected carcinosarcoma of the uterus: a phase II trial by the Japanese Uterine Sarcoma Group and the Tohoku Gynecologic Cancer Unit.
Otsuki A; Watanabe Y; Nomura H; Futagami M; Yokoyama Y; Shibata K; Kamoi S; Arakawa A; Nishiyama H; Katsuta T; Kudaka W; Shimada M; Sato N; Kotera K; Katabuchi H; Yaegashi N
Int J Gynecol Cancer; 2015 Jan; 25(1):92-7. PubMed ID: 25347097
[TBL] [Abstract][Full Text] [Related]
9. Patterns of failure for conservatively managed surgical stage I uterine carcinosarcoma: implications for adjuvant therapy.
Leath CA; Numnum TM; Kendrick JE; Frederick PJ; Rocconi RP; Conner MG; Straughn JM
Int J Gynecol Cancer; 2009 Jul; 19(5):888-91. PubMed ID: 19574779
[TBL] [Abstract][Full Text] [Related]
10. Multimodality adjuvant therapy and survival outcomes in stage I-IV uterine carcinosarcoma.
McEachron J; Heyman T; Shanahan L; Tran V; Friedman M; Gorelick C; Economos K; Singhal PK; Lee YC; Kanis MJ
Int J Gynecol Cancer; 2020 Jul; 30(7):1012-1017. PubMed ID: 32447295
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of uterine carcinosarcoma: results of 94 patients.
Gokce ZK; Turan T; Karalok A; Tasci T; Ureyen I; Ozkaya E; Kose MF; Tulunay G
Int J Gynecol Cancer; 2015 Feb; 25(2):279-87. PubMed ID: 25611900
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy for Uterine Carcinosarcoma with Carboplatin, Ifosfamide and Mesna.
Dandamudi RK; Aslam S; Walji N; El-Modir A; Fernando I
Anticancer Res; 2015 Sep; 35(9):4841-7. PubMed ID: 26254376
[TBL] [Abstract][Full Text] [Related]
13. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.
Krivak TC; Seidman JD; McBroom JW; MacKoul PJ; Aye LM; Rose GS
Gynecol Oncol; 2001 Oct; 83(1):89-94. PubMed ID: 11585418
[TBL] [Abstract][Full Text] [Related]
14. A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma.
Makker V; Abu-Rustum NR; Alektiar KM; Aghajanian CA; Zhou Q; Iasonos A; Hensley ML
Gynecol Oncol; 2008 Nov; 111(2):249-54. PubMed ID: 18755503
[TBL] [Abstract][Full Text] [Related]
15. Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma.
Matsuo K; Omatsu K; Ross MS; Johnson MS; Yunokawa M; Klobocista MM; Im DD; Bush SH; Ueda Y; Takano T; Blake EA; Hasegawa K; Baba T; Shida M; Satoh S; Yokoyama T; Machida H; Adachi S; Ikeda Y; Iwasaki K; Miyake TM; Yanai S; Nishimura M; Nagano T; Takekuma M; Takeuchi S; Pejovic T; Shahzad MM; Ueland FR; Kelley JL; Roman LD
Gynecol Oncol; 2017 Apr; 145(1):78-87. PubMed ID: 28215838
[TBL] [Abstract][Full Text] [Related]
16. Humoral hypercalcemia caused by uterine corpus carcinosarcoma consisting of squamous cell carcinoma in its epithelial component.
Takamatsu S; Matsumura N; Baba T; Mandai M; Mikami Y; Konishi I
J Obstet Gynaecol Res; 2014 Jan; 40(1):263-7. PubMed ID: 24033661
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.
Galaal K; Godfrey K; Naik R; Kucukmetin A; Bryant A
Cochrane Database Syst Rev; 2011 Jan; (1):CD006812. PubMed ID: 21249682
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant pelvic radiotherapy for uterine carcinosarcoma in a high risk population.
Le T
Eur J Surg Oncol; 2001 Apr; 27(3):282-5. PubMed ID: 11373106
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Adjuvant Pelvic Radiotherapy on Distant Metastasis for Uterine Carcinosarcoma.
Eng NL; Rana SR; Hall KL; Eng TY
Am J Clin Oncol; 2021 Apr; 44(4):169-173. PubMed ID: 33481373
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of radiotherapy in patients with primary uterine carcinosarcoma: a multicenter retrospective study (KROG 13-08).
Cha J; Kim YS; Park W; Kim HJ; Kim JY; Kim JH; Kim J; Yoon WS; Kim JW; Kim YB
J Gynecol Oncol; 2016 Nov; 27(6):e58. PubMed ID: 27550404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
